X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (186) 186
humans (154) 154
administration, oral (105) 105
female (73) 73
male (73) 73
tofacitinib (70) 70
dermatology (69) 69
double-blind (68) 68
treatment outcome (65) 65
pharmacology & pharmacy (57) 57
rheumatoid arthritis (57) 57
janus kinase inhibitor (56) 56
psoriasis (55) 55
middle aged (53) 53
methotrexate (52) 52
adult (51) 51
rheumatology (51) 51
arthritis, rheumatoid - drug therapy (50) 50
pyrimidines - administration & dosage (43) 43
pyrroles - administration & dosage (43) 43
arthritis (42) 42
drug therapy (42) 42
clinical trials (41) 41
efficacy (41) 41
piperidines - administration & dosage (40) 40
pyrroles - therapeutic use (39) 39
pyrimidines - therapeutic use (38) 38
safety (36) 36
piperidines - therapeutic use (35) 35
protein kinase inhibitors - administration & dosage (35) 35
animals (33) 33
inadequate response (33) 33
antirheumatic agents - therapeutic use (32) 32
rheumatoid-arthritis (30) 30
abridged index medicus (29) 29
care and treatment (29) 29
dose-response relationship, drug (29) 29
patients (29) 29
analysis (28) 28
oral phosphodiesterase-4 inhibitor (28) 28
protein kinase inhibitors - therapeutic use (28) 28
severity of illness index (28) 28
double-blind method (27) 27
pyrimidines - adverse effects (27) 27
pyrroles - adverse effects (27) 27
cytokines (26) 26
dosage and administration (26) 26
placebo-controlled trial (26) 26
therapy (26) 26
inflammation (25) 25
medicine & public health (25) 25
piperidines - adverse effects (25) 25
placebo (25) 25
aged (24) 24
janus kinases - antagonists & inhibitors (24) 24
psoriasis - drug therapy (24) 24
young adult (24) 24
janus kinase (23) 23
protein kinase inhibitors - adverse effects (22) 22
research (22) 22
antirheumatic agents - administration & dosage (21) 21
drug administration schedule (21) 21
psoriatic arthritis (21) 21
cp-690,550 (20) 20
inflammatory bowel disease (20) 20
drug dosages (19) 19
quality-of-life (19) 19
ulcerative colitis (19) 19
inflammatory-bowel-disease (18) 18
maintenance therapy (18) 18
modifying antirheumatic drugs (18) 18
oral administration (18) 18
randomized controlled-trial (18) 18
internal medicine (17) 17
phase-iii (17) 17
review (17) 17
studies (17) 17
adolescent (16) 16
apremilast (16) 16
health aspects (16) 16
active rheumatoid-arthritis (15) 15
corticosteroids (15) 15
disease (15) 15
drugs (15) 15
gastroenterology & hepatology (15) 15
trial (15) 15
tumor necrosis factor-tnf (15) 15
adalimumab (14) 14
alopecia (14) 14
colitis, ulcerative - drug therapy (14) 14
drug therapy, combination (14) 14
immunology (14) 14
management (14) 14
pathogenesis (14) 14
pharmacokinetics (14) 14
protein kinase inhibitors - pharmacology (14) 14
quality of life (14) 14
skin (14) 14
antirheumatic agents - adverse effects (13) 13
combination (13) 13
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10093, pp. 457 - 468
Summary Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | MODIFYING ANTIRHEUMATIC DRUGS | NECROSIS-FACTOR | PLACEBO | JANUS KINASE INHIBITOR | INADEQUATE RESPONSE | LONG-TERM SAFETY | PLUS METHOTREXATE | AMERICAN-COLLEGE | OPEN-LABEL | COMBINATION | Antirheumatic Agents - administration & dosage | Humans | Middle Aged | Male | Methotrexate - therapeutic use | Adalimumab - adverse effects | Arthritis, Rheumatoid - drug therapy | Pyrroles - administration & dosage | Antirheumatic Agents - adverse effects | Pyrroles - adverse effects | Adult | Female | Drug Therapy, Combination | Pyrroles - therapeutic use | Antirheumatic Agents - therapeutic use | Severity of Illness Index | Piperidines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Pyrimidines - administration & dosage | Treatment Outcome | Methotrexate - adverse effects | Adalimumab - therapeutic use | Adalimumab - administration & dosage | Piperidines - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Methotrexate - administration & dosage | Rheumatoid factor | Care and treatment | Analysis | Clinical trials | Arthritis | Pharmaceutical industry | Methotrexate | Rheumatology | Patients | Evidence-based medicine | Studies | Rheumatoid arthritis | Monoclonal antibodies | Rheumatism | TNF inhibitors | Janus kinase | Tumor necrosis factor-TNF | Safety | Drug therapy | Drug dosages
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2014, Volume 370, Issue 25, pp. 2377 - 2386
In patients with rheumatoid arthritis, tofacitinib was associated with greater reductions in signs and symptoms than methotrexate. Herpes zoster infections and... 
MEDICINE, GENERAL & INTERNAL | MODIFYING ANTIRHEUMATIC DRUGS | ADALIMUMAB | RECOMMENDATIONS | COMBINATION THERAPY | JOINT DAMAGE | DISEASE | PLUS METHOTREXATE | DOUBLE-BLIND | ETANERCEPT | CP-690,550 | Herpes Zoster - etiology | Antirheumatic Agents - administration & dosage | Arthritis, Rheumatoid - blood | Cholesterol - blood | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Arthritis, Rheumatoid - complications | Dose-Response Relationship, Drug | Janus Kinase 3 - antagonists & inhibitors | Arthritis, Rheumatoid - drug therapy | Pyrroles - administration & dosage | Antirheumatic Agents - adverse effects | Pyrroles - adverse effects | Adult | Female | Piperidines - administration & dosage | Double-Blind Method | Administration, Oral | Pyrimidines - administration & dosage | Methotrexate - adverse effects | Protein Kinase Inhibitors - administration & dosage | Piperidines - adverse effects | Pyrimidines - adverse effects | Creatinine - blood | Methotrexate - administration & dosage | Care and treatment | Dosage and administration | Tofacitinib | Comparative analysis | Methotrexate | Rheumatoid arthritis | Creatinine | Herpes zoster | C-reactive protein | Kinases | Joint diseases | Lymphoma | Sedimentation | Cholesterol | Pain | Rheumatism | Janus kinase | Erythrocyte sedimentation rate | Drug therapy | Pharmaceuticals | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2012, Volume 367, Issue 7, pp. 616 - 624
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 16, pp. 1537 - 1550
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 16, pp. 1525 - 1536
Treatment of psoriatic arthritis with the oral Janus kinase inhibitor tofacitinib for 3 months was more effective than placebo in reducing joint... 
MEDICINE, GENERAL & INTERNAL | CANADA SPARCC | CHRONIC PLAQUE PSORIASIS | ENTHESITIS INDEX | SPONDYLOARTHRITIS RESEARCH CONSORTIUM | ACTIVE RHEUMATOID-ARTHRITIS | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | QUALITY-OF-LIFE | HEALTH-ASSESSMENT QUESTIONNAIRE | DISEASE-ACTIVITY | Humans | Middle Aged | Male | Alanine Transaminase - blood | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Pyrroles - administration & dosage | Arthritis, Psoriatic - drug therapy | Treatment Failure | Pyrroles - adverse effects | Adult | Female | Drug Therapy, Combination | Pyrroles - therapeutic use | Antirheumatic Agents - therapeutic use | Disability Evaluation | Piperidines - administration & dosage | Double-Blind Method | Administration, Oral | Pyrimidines - administration & dosage | Janus Kinases - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Aspartate Aminotransferases - blood | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Placebos | Dosage and administration | Research | Tofacitinib | Tumor necrosis factor | Myocardial infarction | Cerebral infarction | Alanine | Herpes zoster | Inhibitor drugs | Psoriasis | Cytokines | Arthritis | Patients | Ischemia | Alanine transaminase | TNF inhibitors | Janus kinase | Tumor necrosis factor-TNF | Drug therapy | Drug dosages
Journal Article
Journal Article
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 06/2017, Volume 101, Issue 6, pp. 745 - 753
Extended‐release (XR) formulations enable less frequent dosing vs. conventional (e.g., immediate release (IR)) formulations. Regulatory registration of such... 
RISK-FACTORS | PEDIATRIC-PATIENTS | PHARMACOGENOMICS | INFANTS | PHARMACOLOGY & PHARMACY | ADVERSE DRUG-REACTIONS | PHARMACOVIGILANCE | ANAPHYLAXIS | EPIDEMIOLOGY | CHILDREN | HYPERSENSITIVITY | Pyrroles - pharmacokinetics | Area Under Curve | United States | Humans | Male | Metabolic Clearance Rate | Drug Approval | Janus Kinases - metabolism | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Pyrimidines - chemistry | Protein Kinase Inhibitors - chemistry | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Models, Animal | Piperidines - pharmacokinetics | Antineoplastic Agents - pharmacokinetics | United States Food and Drug Administration | Protein Kinase Inhibitors - pharmacokinetics | Piperidines - administration & dosage | Piperidines - chemistry | Drug Administration Schedule | Administration, Oral | Pyrimidines - administration & dosage | Neoplasms - enzymology | Treatment Outcome | Antineoplastic Agents - chemistry | Rats, Sprague-Dawley | Neoplasms - drug therapy | Janus Kinases - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Animals | Models, Biological | Pyrimidines - pharmacokinetics | Pyrroles - chemistry | Neoplasms - pathology | Delayed-Action Preparations | Therapeutic Equivalency | Treatment outcome | Care and treatment | Tofacitinib | Analysis | Rheumatoid arthritis | Dosage and administration | Pharmacokinetics | Index Medicus | Abridged Index Medicus | Research
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 05/2016, Volume 75, Issue 5, pp. 831 - 841
ObjectivesTofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). To further assess the potential role of Janus kinase... 
JAK INHIBITOR | MODIFYING ANTIRHEUMATIC DRUGS | Rheumatoid Arthritis | INADEQUATE RESPONSE | Inflammation | RHEUMATOLOGY | PSORIATIC-ARTHRITIS | LONG-TERM EXTENSION | BACKGROUND METHOTREXATE | FACTOR THERAPY | DMARDs (synthetic) | Treatment | DOUBLE-BLIND | NECROSIS-FACTOR INHIBITORS | SKIN-CANCER | Antirheumatic Agents - administration & dosage | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Incidence | Dose-Response Relationship, Drug | Janus Kinase 3 - antagonists & inhibitors | Young Adult | Clinical Trials, Phase III as Topic | Multicenter Studies as Topic | Neoplasms - chemically induced | Arthritis, Rheumatoid - drug therapy | Pyrroles - administration & dosage | Antirheumatic Agents - adverse effects | Pyrroles - adverse effects | Adult | Female | Pyrroles - therapeutic use | Antirheumatic Agents - therapeutic use | Piperidines - administration & dosage | Administration, Oral | Pyrimidines - administration & dosage | Randomized Controlled Trials as Topic | Protein Kinase Inhibitors - administration & dosage | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Adolescent | Pyrimidines - adverse effects | Aged | Neoplasms - epidemiology | Clinical Trials, Phase II as Topic | Clinical trials | Care and treatment | Usage | Dosage and administration | Tofacitinib | Rheumatoid arthritis | Clinical and Epidemiological Research | 1506
Journal Article